机构名称：
¥ 1.0
Dexamethasone : EMEND when given as a regimen of 125 mg with dexamethasone co- administered orally as 20 mg on Day 1, and EMEND when given as 80 mg/day with dexamethasone co-administered orally as 8 mg on Days 2 through 5, increased the AUC of dexamethasone, a CYP3A4 substrate by 2.2-fold, on Days 1 and 5.当与变形（125 mg/80 mg方案）共同管理时，应将通常的口服地塞米松剂量减少约50％，以实现与不给未经粉碎时给出的那些相似的地塞米松的暴露。在临床化疗中给药的地塞米松的每日剂量引起的恶心和呕吐研究反映了地塞米松剂量的降低约50％（请参阅第4.2节）。
第三代芳香酶抑制剂和肌腱疾病
主要关键词
相关文件推荐
